Premium
P4–281: Targeting cyclooxygenase–derived levuglandins as potentially novel therapeutic approaches to Alzheimer's disease
Author(s) -
Boutaud Olivier,
Zagol-Ikapitte IrÃn̈e,
Amarnath Venkataraman,
Yermalitsky Valery,
Andreasson Katrin I.,
Montine Thomas J.,
Oates John A.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.2020
Subject(s) - cyclooxygenase , lysine , chemistry , adduct , hippocampus , alzheimer's disease , gene isoform , prostaglandin e2 , cysteine , enzyme , genetically modified mouse , prostaglandin , senile plaques , biochemistry , pharmacology , transgene , medicine , disease , amino acid , gene , organic chemistry
ELISA-type assays, allowed the isolation of a panel of Nanobodies with different binding-capacity and specificity. Selected Nanobodies were characterized for their biochemical and immuno-histochemical specificity, respectively by Western blotting and on brain sections of APP[V717I] transgenic mice, our validated model for amyloid pathology in AD. The combination of classical and urea/SDS-PAGE with immunoblotting and histo-amyloid-reactivity resulted in the selection of several Nanobodies differing in specificity, i.e. reacting with all A , with A 42, and/or with amyloid plaques. The latter was confirmed in vivo by intra-cerebral injection. Conclusions: Based on the selected Nanobodies, we derived bivalent and bispecific Nanobodies that are directed to different molecular targets, as well as others that can actively pass the blood-brain barrier, aiming at therapeutic and diagnostic purposes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom